The evolution of the randomized controlled trial and its role in evidence‐based decision making

Abstract

The randomized controlled trial has been used in medical research for a little over half a century. This manuscript provides an overview of some of the history and evolution of the randomized controlled trial during this period. There exists hierarchies of evidence for therapeutic, diagnostic and prognostic questions, and the randomized controlled trial is at the top of the therapeutic hierarchy. Despite being at the top of the therapeutic hierarchy randomization in itself does not guarantee the trial results approximate the true effect. Issues that result in systematic and nonsystematic deviations from the truth in randomized controlled trials must also be considered. We present a model for evidence-based decision making that includes the following components: the clinical state, patient preferences, research evidence from a range of studies and clinical expertise. We discuss the role of the randomized controlled trial within evidencebased decision making.

Risks and benefits of -blockade

“…Finally, relative risk reductions beyond 35% are now extremely uncommon; hence our description of such results as "too good to be true." 5 The results of the MaVS trial 2 reinforce the message that perioperative β-blockers have risks and as-yet-unproven benefits. Fortunately, a large, adequately powered trial that is now in progress, the PeriOperative Ischemic Evaluation (POISE) trial, should definitively establish the effect of perioperative β-blocker therapy in patients undergoing noncardiac surgery.…”

When Ethics Constrains Clinical Research: Trial Design of Control Arms in “Greater Than Minimal Risk” Pediatric Trials

“…Indeed, some argue that RCTs provide the most objective, legitimate, and genuinely scientific evidence about the effectiveness of any medical procedure (Guyatt et al, 2000;Devereaux and Yusuf, 2003). Hence, even when there is a clear recognition of the challenges that randomized clinical trials would impose on the development of drugs for rare, fatal diseases, and even when other trial designs are thought to be necessary in order to allow for needed medicines (Buckley, 2008;Griggs et al, 2009;Mitsumoto et al, 2009;Anonymous, 2010), the general agreement is that randomized clinical trials would provide the best evidence.…”

Guest Editorial — Evolution: a useful philosophy for physiotherapy research

“…The most obvious example is the randomized controlled trial. The fi rst randomized controlled trial described the use of streptomycin for tuberculosis (MRC, 1948;Devereaux and Yusuf, 2003), whereas the fi rst clinical trials in physiotherapy (manipulation for low back pain and wax baths for rheumatoid arthritis) occurred several years later (Moseley et al, 2002). The physiotherapy research philosophy de jour is evidence-based practice, which, again, follows on from a medical practitioner-based initiative.…”